In January, the Food and Drug Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex Pharmaceuticals. It’s the first time in 25 years the agency has given the green light to a new painkiller. Notably, it’s not an opioid and, according to the company, it’s not addictive. Unlike opioids, which act directly on the brain, Journavx instead blocks nerve endings across the body that transmit pain.
Host Ira Flatow is joined by Dr. Sean Mackey, a professor of anaesthesiology and pain medicine at Stanford University and chief of the Division of Stanford Pain Medicine, to discuss how the new drug works, who should take it, and what its limitations are.
Further Reading
- Read more about Journavx via its manufacturer, Vertex Pharmaceuticals.
Donate To Science Friday
Invest in quality science journalism by making a donation to Science Friday.
Segment Guests
Sean Mackey
Dr. Sean Mackey is a professor of anesthesiology and pain medicine and Chief of the Division of Stanford Pain Medicine at Stanford University in Stanford, California.
Segment Transcript
The transcript of this segment is being processed. It will be available early next week.
Meet the Producers and Host
About D Peterschmidt
D Peterschmidt is a producer, host of the podcast Universe of Art, and composes music for Science Friday’s podcasts. Their D&D character is a clumsy bard named Chip Chap Chopman.
About Ira Flatow
Ira Flatow is the founder and host of Science Friday. His green thumb has revived many an office plant at death’s door.